Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

In this piece, we will look at the stocks Jim Cramer discussed.

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling Palantir - whose stock has more than doubled this year on AI excitement and ...

Asian shares were trading mixed on Tuesday after overseas markets got a big lift from optimism over AI technology. Japan’s benchmark Nikkei 225 dipped 0.5% to 52,163.84, coming ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

As equity markets face sustained volatility, investors are actively seeking high-quality assets that can withstand economic ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health ...